Form 4: Corbus Pharmaceuticals Director Avery Catlin Reports Stock Grant
SEC Form 4 Filing
Director Avery Catlin reports the grant of restricted stock units (RSUs) in Corbus Pharmaceuticals.
Summary
- On May 30, 2024, Avery Catlin, a director of Corbus Pharmaceuticals Holdings, Inc., was granted 2,783 restricted stock units (RSUs).
- These RSUs will vest 100% on the one-year anniversary of the grant date.
- Following this transaction, Catlin beneficially owns 4,350 shares, including the unvested RSUs.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of an RSU grant, which is a common practice.
Positives
- The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing performance and long-term value creation.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider transactions, allowing investors to stay informed about the actions of company directors and officers.
Stakeholder Impact
- The RSU grant aligns the director's interests with shareholders, potentially leading to better corporate governance and decision-making.
Key Dates
| Date | Description |
|---|---|
| 2024-03-08 | Date of Power of Attorney execution. |
| 2024-05-30 | Date of RSU grant. |
| 2025-05-30 | RSUs vest 100%. |
| 2024-06-03 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.